Glaxosmithkline Llc patents expiration
1. Lamictal Cd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5698226 (Pediatric) | GLAXOSMITHKLINE LLC | Water-dispersible tablets |
Jul, 2012
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | May 18, 2018 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 24 August, 1998
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
LAMICTAL CD family patents
2. Lamictal Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919115 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jan, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8840925 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(4 years from now) | |
| US9339504 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | May 18, 2018 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 08 May, 2009
Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
LAMICTAL ODT family patents
3. Lamictal Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144547 | GLAXOSMITHKLINE LLC | Oral dosage form for controlled drug release |
Sep, 2023
(6 months ago) | |
| US8637512 | GLAXOSMITHKLINE LLC | Formulations and method of treatment |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 29, 2012 |
| New Indication(I-644) | Apr 25, 2014 |
| New Indication(I-622) | Jan 29, 2013 |
| Pediatric Exclusivity(PED) | Nov 29, 2012 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 29 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
LAMICTAL XR family patents
4. Mepron patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6649659 | GLAXOSMITHKLINE LLC | Atovaquone pharmaceutical compositions |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6649659 (Pediatric) | GLAXOSMITHKLINE LLC | Atovaquone pharmaceutical compositions |
Jan, 2017
(7 years ago) | |
Drugs and Companies using ATOVAQUONE ingredient
Market Authorisation Date: 08 February, 1995
Treatment: Treatment of pneumocystis carinii infections
Dosage: SUSPENSION;ORAL
MEPRON family patents
5. Requip Xl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8303986 | GLAXOSMITHKLINE LLC | Hydrophilic/lipophilic polymeric matrix dosage formulation |
Apr, 2021
(3 years ago) | |
| US7927624 | GLAXOSMITHKLINE LLC | Hydrophilic/lipophilic polymeric matrix dosage formulation |
Dec, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-203) | Mar 23, 2020 |
Drugs and Companies using ROPINIROLE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 June, 2008
Treatment: A process for treating a patient suffering from parkinson's syndrome and in need of treatment
Dosage: TABLET, EXTENDED RELEASE;ORAL
REQUIP XL family patents
6. Rythmol Sr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5681588 | GLAXOSMITHKLINE LLC | Delayed release microtablet of β-phenylpropiophenone derivatives |
Oct, 2014
(9 years ago) | |
Drugs and Companies using PROPAFENONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 September, 2003
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RYTHMOL SR family patents